drugset / Trial / NCT05367440
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.
Timeline
- Start
- 2022-06-02
- Primary completion
- 2031-04-11
- Completion
- 2031-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | — | Oral |
| Subject | Apalutamide | Small molecule | — | Oral |
| Subject | Darolutamide | Other / unclassified | — | Oral |
| Subject | Enzalutamide | Other / unclassified | — | Oral |
| Subject | Saruparib | Small molecule | — | Oral |